CLINICAL TRIALS PROFILE FOR BECONASE AQ
✉ Email this page to a colleague
All Clinical Trials for BECONASE AQ
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00115089 ↗ | 7 Day Study of Mast Cell Inhibitor, R926112, in Patients With Symptomatic Seasonal Allergic Rhinitis | Completed | Rigel Pharmaceuticals | Phase 2 | 2005-07-01 | This is a study of the effectiveness and safety of a new nasal spray for the relief of the symptoms of seasonal allergies. The agents being compared are: R926112 (a novel anti-allergy medicine), Beconase (beclomethasone dipropionate, an established FDA approved steroid treatment), and an inactive placebo. The study hypothesis is that R926112 will be superior to placebo at the end of a week of testing and evaluation. The study does not have the power to determine how R926112 compares to Beconase. |
| NCT00489203 ↗ | Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | Completed | Fred Hutchinson Cancer Research Center | Phase 2 | 2007-04-01 | RATIONALE: Beclomethasone dipropionate may be effective in preventing acute graft-versus-host disease in patients undergoing a stem cell transplant for hematologic cancer. PURPOSE: This randomized phase II trial is studying how well beclomethasone dipropionate works in preventing acute graft-versus-host disease in patients undergoing a donor stem cell transplant for hematologic cancer. |
| NCT00775489 ↗ | Nasal Steroids in Controlled Glaucoma | Completed | Glaucoma Research Society of Canada | N/A | 2010-01-01 | Patients that have consented to participate in the study will be randomly assigned to one of two groups: control group or nasal steroid group. Patients in the control group will receive normal saline inhaler. Patients in the study group will receive steroid inhaler Follow-up visits are: baseline and weeks 2, 4, 6 after starting the spray. Intraocular pressure will be recorded on all visits. |
| NCT00775489 ↗ | Nasal Steroids in Controlled Glaucoma | Completed | University Health Network, Toronto | N/A | 2010-01-01 | Patients that have consented to participate in the study will be randomly assigned to one of two groups: control group or nasal steroid group. Patients in the control group will receive normal saline inhaler. Patients in the study group will receive steroid inhaler Follow-up visits are: baseline and weeks 2, 4, 6 after starting the spray. Intraocular pressure will be recorded on all visits. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for BECONASE AQ
Condition Name
| Condition Name for BECONASE AQ | |
| Intervention | Trials |
| Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | 1 |
| Stage II Cutaneous T-cell Non-Hodgkin Lymphoma | 1 |
| Isolated Plasmacytoma of Bone | 1 |
| Stage IV Grade 2 Follicular Lymphoma | 1 |
| [disabled in preview] | 0 |
| This preview shows a limited data set Subscribe for full access, or try a Trial | |
Clinical Trial Locations for BECONASE AQ
Trials by Country
Clinical Trial Progress for BECONASE AQ
Clinical Trial Phase
Clinical Trial Sponsors for BECONASE AQ
Sponsor Name
